Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

NCT06577532 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neoplasms
Other Solid Tumors

Interventions

DRUG: ABO2102
DRUG: Toripalimab

Sponsor

Ruijin Hospital

Collaborators

[object Object]